$INO -The Realistic Bull Case for $INO to $1.50: Why the Market is Mispricing the $80M Win Ahead of October 30 The headline $80.4 million court award spiked $INO by over 20% before profit-taking brought it back to earth. While retail calls for $3.00+ ignore share count and warrant math, $1.50 is a realistic, mathematically grounded near-term target. Here is the breakdown of why $1.50 makes fundamental sense and how the next 10 days could trigger the move: 1. The Math: What Does $1.50 Actually Mean? Current Share Count: ~103.4 million shares Market Cap at $1.00: ~$103.4 million Market Cap at $1.50: ~$155.1 million Added Value Needed: +$51.7 million At $1.50, the market only needs to price in a probability-weighted recovery of the litigation ($20M–$30M in real value) combined with lead pipeline validation. That is completely within reach.

$INO -Appellate Mechanics and the Supersedeas DilemmaUnder Pennsylvania civil procedure, obtaining a final trial court judgment does not trigger immediate cash disbursement if the defendants pursue post-trial motions or appeals. However, Pennsylvania law places stringent security requirements on judgment debtors seeking to stay execution pending appeal.The 120% Supersedeas Bond RequirementPursuant to Pennsylvania Rule of Appellate Procedure 1731(a) (Pa. R.A.P. 1731(a)), an appeal from an order involving solely a monetary award does not operate as an automatic supersedeas (stay of execution) unless the appellant posts security in the amount of 120% of the judgment amount found due and unpaid, plus interest and anticipated delay costs.$$\text{Required Supersedeas Security} = \$80,416,101 \times 120\% = \$96,499,321.20$$COMMERCIAL sureties require corporate appellants to deposit 100% liquid collateral—typically cash, irrevocable letters of credit, or investment-grade securities—before underwriting an appeal bond of this size, alongside an annual premium running approximately 1% of the bonded total. Because GeneOne’s market capitalization is approximately $35 million and its cash balances are limited, neither GeneOne nor VGXI has the liquidity required to collateralize a $96.5 million surety bond.

$VCIG - separating the AI catalyst from the financing and float confusion VCI Global announced on October 6 at 3:45 p.m. ET that its VGAIN Compute platform is live, allowing users to purchase AI usage tokens to access supported models, including GPT, Kimi, Llama and Qwen. This is a company-confirmed product launch. Supporting those models does not establish partnerships with their developers, and “AI tokens” here does not establish a cryptocurrency launch. The release does not disclose paying customers, revenue or margins. Announcement The $125M financing headline is not $125M cash received. It describes conditional equity-purchase capacity. The associated Form D reports $0 sold under that offering. The financing includes discounted share-purchase mechanics and warrants, creating potential dilution. Conversely, proposed registration of up to 111.6M shares does not mean all those shares are already outstanding or available to sell today. Form D, F-1 Treat float claims cautiously. The September 29 filing reports 2.077M outstanding shares. Adding the subsequent 193,349-share CEO subscription produces approximately 2.271M basic shares, assuming no other changes. A reconstruction after identified insider/restricted holdings suggests roughly 1.9M, but that is not a confirmed current float. Sub-500K claims should not be treated as established. CEO filing Book value is not a price target. At December 2025, the company reported $116.9M in assets, including a $62.8M related-party receivable, versus approximately $941K cash and $20.7M liabilities. Those historical balances require updated collection and financing information before translating them into per-share value. Annual report VCIG has a genuine product announcement and speculative upside potential. It does not yet have disclosed platform economics supporting a reliable intrinsic-value target. Neither “guaranteed squeeze” nor “all the financing shares are dumping now” is established by the evidence. Watch for customer adoption, cash collections, actual issuance and sustained buying not just headline size.

$SNDK - One of the fascinating charts ever. It took almost a year to find its ATH (which itself was a record and wealth creator) now the rate it is coming down is unparalleled. No support at all. Let's see what happens in the next few days. We can only speculate. None of us know

$HPE - Friday movement. It is not just because of DELL sympathy.. the fundamental backdrop kept the bids firm ahead of the mi day earnings : Activists & Insiders: Elliott Management's newly expanded 27.4M share stake continues to fuel structural optimization hopes. Balance Sheet De-leveraging: $HPE disclosed the monetization of its H3C stake for roughly $987M, giving them clean capital to pay down debt post-Juniper.

$HPE -Can it hit $50 after hours on Monday ? If HPE drops a true beat after the close (EPS well above the $0.55 whisper, an expansion of the $5B AI backlog, and a major upward revision to full-year FY26 guidance), the 10.6% post-market implied volatility will unlock. A 12% to 15% gap up from a $44 baseline in late-theater trading is exactly where a squeeze to $50 would happen

$CRCL -Speculation only.. bullish, specifically anticipating a high probability of a short squeeze that pushes the stock into the $130.00 to $134.00 range, or potentially higher. Here is the data-driven rationale for this bullish lean: 1-The CLARITY Act is a Massive De-Risking Event: The recent bipartisan compromise on the CLARITY Act explicitly protects the transaction-based rewards that Circle relies on for its business model. This fundamentally removes the existential regulatory overhang that was depressing the stock, paving the way for institutional adoption. 2-The "Powder Keg" Short Setup: Short sellers have aggressively targeted the stock due to fears of margin contraction, with short interest jumping 22.4% recently to cover 12.2% of the float. Even more telling, the daily short volume ratio surged to a staggering 48.11% of all trading volume just days before the earnings blackout. If Circle reports even mildly positive forward guidance regarding their high-margin software services, these short sellers will be forced to rapidly buy back shares to cover their positions, creating a violent upward price spike. 3-Historical Precedent: Circle has a history of massive post-earnings rallies. Following their last earnings report in February, the stock surged 35.5% in a single day after beating EPS estimates. While the high valuation and recent insider selling (which was largely pre-scheduled via 10b5-1 plans) provide ammunition for the bears, the structural setup in the options market and the heavily squeezed float suggest the path of least resistance is a violent move upward. If management executes a strong earnings call, expect the stock to hit the top of the options market's 15% expected move (around $130) and potentially challenge Wells Fargo's recent $142.00 price target.

$SHAZ- The $SHAZ "Sovereign AI" Inflection: A $1.25B Masterclass 1/ The Catalyst: SharonAI ($SHAZ) just dropped a nuclear-grade 8-K. A 5-year, $1.25 Billion Master Infrastructure Agreement with ESDS Software Solutions. The Scale: For a ~$445M market cap company, this is a TCV-to-Cap ratio of 2.8x. The Math: Amortized over 60 months, that’s ~$250M/year in high-margin recurring revenue. 2/ The Hardware Moat: This isn't a "pilot" program. It’s a deployment of 8,200 NVIDIA B300 (Blackwell Ultra) GPUs. The Performance: 14 PFLOPS dense FP4 compute 55% faster than the B200. The Infrastructure: 1,400W TDP per GPU requires Direct Liquid Cooling (DLC). The Edge: $SHAZ has 70MW of Tier IV capacity secured at @NEXTDC M3 in Melbourne. In a power-constrained world, Capacity = Alpha. 3/ Counterparty De-Risking: The bear case today was skepticism over ESDS’s ability to pay. The 8-K silenced this with cold data: Security: ESDS is mandated to provide $140M in Letters of Credit/Bank Guarantees. Lock-in: No "Termination for Convenience" in the first 36 months. This isn't "hope"; it's a collateralized asset. 4/ Financial Engineering: $SHAZ is scaling without the "Death Spiral" dilution common in tech micro-caps. USD.AI Facility: A $500M non-recourse, asset-backed debt engine. The Tech: Financing via stablecoin liquidity against verified GPU hardware. The Result: Massive scaling of the "AI Factory" while keeping the float tight (~10.8M share float). 5/ The Tape (The "Gap & Crap" Recovery): Today was a textbook technical shakeout. The Open: Gapped to $25.80. The Trap: Flushed to an intraday low of $22.54 to shake out "paper hands." The Absorption: Heavy institutional accumulation drove a recovery to close at $27.62 (+21.5%). 6/ Valuation Framework: If $SHAZ executes on a $275M-$300M revenue run-rate: Peer Multiples: Neocloud peers (CoreWeave/Lambda) trade at 8x-12x Revenue. Conservative 6x Multiple: Implies a $1.8B Market Cap. Target: With current share structure, "Fair Value" sits north of $75.00 as the market prices in the backlog. 7/ The Verdict: We are witnessing an Episodic Pivot (A+ Catalyst). Today was Day 1 of the structural re-rating. Once the market reclaims the $30.00 IPO price, we enter "Blue Sky" territory.

$RZLV- Not bad for 22% spike today.. . sometimes analysis do work. sometimes it does not..

$RZLV -$RZLV 20-F ALERT: The "Audit" is In – Hypergrowth Validated-sec.gov/Archives/edgar/data/… wait is over. Rezolve AI has officially filed its Form 20-F Annual Report with the SEC. If you were looking for the "Green Light" that separates speculative AI rumors from production-grade reality, this is it. -The "Triple Crown" Metrics The 543% Growth Flip: 2025 revenue hit $46.8M, but the real story is the H2 acceleration. Revenue skyrocketed 543% in the second half vs. the first half as major deployments went live. The "Floor" is Set: The company exited the year with $19.4M in December MRR, establishing a $232M+ Annualized Run Rate (ARR). This provides a massive, high-conviction foundation for their raised $360M revenue guidance for 2026. Software-Elite Margins: Blended gross margins are at 66%, but the core software component is performing at 90%+. This is the structural profitability "Whales" look for in the SaaS/AI sector. -The "Fully Funded" Mandate The biggest "short" thesis on small-cap AI is always dilution. The 20-F just killed that narrative. Cash Position: $111.1M as of year-end. Capital Fortress: With over $750M in total funding secured (including the oversubscribed Jan raise), the Company explicitly stated they have "zero requirement for additional operational equity" to execute their 2026 mission. -Strategic Edge: Agentic Commerce This isn't just "Search." Rezolve has processed 112.7 billion API calls across 950+ enterprise customers. They are moving from the "Experimentation Phase" into Live Infrastructure. 📉 The Technical Setup (Tuesday Morning) The Gap: The stock is already showing relative strength, drifting green overnight as the "Compliance Risk" of the missing 20-F is removed. T Bottom Line: The 20-F proves the "Hockey Stick" is real. $RZLV is no longer a concept it’s an infrastructure leader trading at a massive discount to its Forward ARR. #RZLV #AI #AgenticCommerce #Squeeze #StockMarket

$RZLV -The $RZLV numbers this morning are essentially a masterclass in AI scaling. While the "Tape" is playing tug-of-war at the $2.60 level, the fundamental re-rating is hard to ignore: 🔹 The Growth: 543% H2 revenue surge vs. H1. 🔹 The Guide: 2026 revenue raised to $360M (well above previous $310M estimates). 🔹 The Floor: Exited 2025 with $232M in contracted ARR. That's a massive safety net for a ~$1B market cap. 🔹 The Cash: $750M+ total funding. The "dilution" bear case is officially dead. Why the stagnation? Look at the data: Shorts borrowed 2.5M+ shares today alone to hold this back, and there's a massive Call Wall at $3.00. The Setup: Historically, $RZLV is a "Day 2" mover (Avg +15% continuation). If this clears the $2.89 HOD, the shorts are trapped with near-zero availability to borrow more. Watching the 20-F filing today as the final "green light" for the Whales. 🐳 #AI #Stocks #Trading #RZLV $RZLV

$IBRX 48-Hour Forensic Update: The "Quiet" Battle for the Floor. It has been two days since the FDA Warning Letter triggered a -21% shock. While the narrative has been dominated by "Management Risk," the actual data from the last 48 hours tells a story of aggressive institutional defense and clinical validation. 1. The Clinical Counter-Punch (March 26) While management is effectively "benched" from making promotional claims, they just dropped a massive clinical update this morning. QUILT-2.005 Milestone: The Independent Data Monitoring Committee (IDMC) confirmed the pivotal trial for BCG-Naïve patients (first-line) is adequately powered to show statistical significance. Why this matters: This isn't the "failed" monotherapy cohort. This is the primary expansion market. A supplemental BLA (sBLA) for this multi-billion dollar indication is now officially on track for Q4 2026. This effectively separates the "marketing noise" from the "clinical signal." 2. Technical Resilience: The $7.20 Floor The "Flush" Reversal: On March 24, the stock hit a terrifying low of $6.54. The Recovery: Since that low, the stock has battled back to hold the $7.30–$8.00 range. Today (March 26), it even tested $8.43 before the shorts attempted to cap it. Volume Analysis: After the 86M share "liquidation" on Tuesday, volume has normalized, suggesting that the "Panic Sellers" have been flushed out and replaced by "Whale" accumulation. 3. Market Microstructure: The Short Squeeze Setup The "Silence Trap" we anticipated is backfiring on the shorts: Utilization remains at 100%: There is zero "legal" inventory left to borrow. Cost to Borrow (CTB): Has surged to 17% today. Shorts are paying a heavy premium to bet against a company that just confirmed its trial is powered for success. Put-Call Ratio: The 1.32 ratio for the March 27 weekly expiration shows high bearish positioning the exact fuel needed for a "gamma squeeze" if the stock reclaims $8.50. 4. Regulatory Reality Check SEC EDGAR Audit: Still no 8-K responding to the FDA or new equity offerings. Management is following the 15-day compliance window to the letter. The May 8 "Ace": The market is waiting for the sBLA Acceptance for the Papillary indication. If that drops during this high-CTB/Low-inventory environment, the recovery to $10.00+ could be instantaneous. Final Verdict The "Management Silence" is a legal requirement, not a sign of failure. The clinical data (QUILT-2.005) is the true north. We are currently watching the shorts pay 17% interest to defend a "marketing" headline while the clinical value continues to compound. Capital preservation was the play on Tuesday. Strategic observation is the play today. #IBRX #ANKTIVA #BiotechIntel #StockMarket

$DNLI-AVLAYAH is widely considered the most significant biotech catalyst of 2026: 1. It Solves the "Holy Grail" of Biology For 30 years, the biggest "graveyard" in medicine has been the Blood-Brain Barrier (BBB). Thousands of drugs have failed because they simply couldn't get into the brain. • The Significance: AVLAYAH is the first-ever medicine to use a "Transport Vehicle" (TV) to trick the brain into letting it pass. • The Impact: By approving this, the FDA didn't just approve one drug; they validated a delivery platform that can now be used for Alzheimer’s, Parkinson’s, and ALS. This is the "Intel Inside" moment for brain medicine. 2. The "Competitive Vacuum" In February 2026, the FDA rejected REGENXBIO’s gene therapy for Hunter syndrome. • The Reality: That rejection left the entire market wide open. Denali now has a monopoly on treating the neurological symptoms of this disease. In the world of rare diseases (Orphan Drugs), a monopoly usually leads to massive, high-margin revenue and a multi-billion dollar valuation "re-rating." 3. The "Royalty Pharma" Stamp of Approval Royalty Pharma (the "Whale of Whales" in biotech funding) didn't just bet on Denali they put $275 million on the line specifically for this approval. • The Significance: These guys are the smartest math-minds in the sector. They don't gamble. Their $275M investment was a "pre-approval" bet that the TV platform was worth billions.

$DNLI- WHY WAS IT REMOVED? (THE "GHOST" LISTING) 1.Administrative "Fat Finger" or Early Sync: The FDA’s digital databases (Drugs@FDA, Orange Book, etc.) often sync data from internal review servers to public servers in "batches." It is highly common for a drug to be populated onto the public site hours or even days before the official announcement, and then pulled down once the agency realizes the public has spotted it before the formal 8-K filing or press release. 2.Staging for the News: This is a strong signal that the Approval Letter has likely been signed, and the FDA web team was simply "staging" the page. The removal is a "clean-up" to ensure the official announcement follows the proper regulatory protocol. 3.Historical Precedent: We saw this exact behavior with several high-profile approvals (e.g., Biogen’s Leqembi). The "leak" through the database leads to a pre-market spike, the removal causes a temporary "dip" of uncertainty, and the official press release finally triggers the real squeeze.

$DNLI- $DNLI: Technical & Regulatory Synthesis — April 5 PDUFA As Denali Therapeutics approaches the FDA decision for tividenofusp alfa (DNL310), the equity exhibits a rare convergence of institutional accumulation and mechanical supply constraints. 1. Institutional Activity at Current Levels Level 2 tape captured a ~237k share print (~$5M+) at $20.97 during the March 24 session suggesting meaningful institutional participation at this price zone ahead of the catalyst window. 2. Clinical De-risking Phase 1/2 data demonstrated a 91% reduction in CSF heparan sulfate the key CNS biomarker of disease published in the NEJM. CMC review is complete, materially reducing the probability of a technical rejection. 3. Mechanical Gamma Trap The April 17 option chain shows concentrated Open Interest at the $22.50 strike (832 contracts). A sustained move through $22.50 triggers a Gamma Flip forcing market makers into a pro-cyclical delta-hedging cycle that mechanically accelerates price discovery higher. 4. Liquidity Bottleneck 9.63 Days to Cover. NYSE closed Good Friday April 3. Short sellers have a compressed 7-trading-day window to de-risk ahead of the binary. This creates a structural time-decay trap for the bearish thesis. 5. Platform Optionality 3,050 June $30 calls represent the largest single OI block in the entire chain. The market isn't just pricing tividenofusp alfa — it's beginning to re-rate Denali's broader Blood-Brain Barrier Transport Vehicle platform across Sanfilippo, Pompe, and Alzheimer's programs. 6. The Terminal Exit Risk/reward remains optimal for a Pre-PDUFA Drift strategy. The terminal liquidity point is Thursday April 2. The path of least resistance points toward the 52-week high of $23.77 and the secondary liquidity zone of $25.00. Not financial advice. Do your own work. $966M cash. Breakthrough Therapy designation. No AdCom. Cleared competition. Clock is ticking. ⏱️ #DNLI #Biotech #MarketMechanics #InstitutionalFlow

$IBRX- Tough end of day report - March 24th 2026. Part of investing. $IBRX Forensic Recap: March 24, 2026 Today was a masterclass in how regulatory news collides with extreme market microstructure. The long-term Anktiva thesis hasn't changed but today's -21% crash was driven by a specific information shock. --- 1/ THE CATALYST: FDA Warning Letter FDA Warning Letter MARCS-CMS 725468 was issued March 13 but not publicly disclosed until the FDA posted it on their website today, March 24. During that window, the company announced major wins the NCCN Guideline update (Mar 17) and Macau Approval (Mar 20). IMPORTANT: Companies are not always required to file an 8-K for warning letters materiality is a judgment call. We are not alleging deliberate concealment. What we are saying is the timing created an information asymmetry that the market repriced violently today. --- 2/ THE "SLAP" The FDA cited "false or misleading" claims in: • A direct-to-consumer TV ad featuring CEO Adcock & Dr. Soon-Shiong • A Jan 19 podcast on The Sean Spicer Show Key violations: • Implied Anktiva could "treat all cancers" • Described it as a "cancer vaccine" not an approved label • Showed arm injections (it's delivered intravesically into the bladder) • Zero risk disclosures in the podcast This is their THIRD FDA enforcement action in 6 months. That pattern matters. --- 3/ STATUS This is a marketing/compliance issue NOT a clinical one.Anktiva's 700% revenue growth is real. The FDA is not questioning the science or the approval. They're questioning how management is talking about it publicly. The company has 15 *working* days to respond (~April 15). Expect relative quiet from management during this period as they coordinate their response. --- 4/ PRICE ACTION • Open: $9.07 • Intraday low: $6.54 (-30% peak-to-trough) • Close: ~$7.42 (showed real resilience off lows) • Volume: ~86.9M shares roughly 4x avg daily volume That closing bounce matters. It suggests some buyers stepped in at the lows. But the structure is damaged short-term. --- 5/ SHORT INTEREST & THE SILENCE TRAP Short interest remains ~35.41% of float (~132M+ shares short). Borrow utilization is pinned near 100%. With management now in a regulatory response period (~15 working days), expect a relative news vacuum. Shorts will likely use this silence to test the $6.00–$6.50 support zone. Note: High "Short Exempt" volume seen today reflects legal market-maker exemptions to the uptick rule NOT naked short selling. Important distinction. --- 6/ THE BOTTOM LINE The science hasn't changed. The revenue trajectory hasn't changed. But management credibility has taken a hit both from the content of the letter AND the timing of its disclosure. We are now in a high-volatility "wait and see" period. Two catalysts that can reset the narrative: 📍 ~April 20 — Saudi Arabia commercial launch 📍 ~May 8 — FDA sBLA filing decision (papillary bladder cancer) Not financial advice. Do your own due diligence. Patience and capital preservation are the only plays here. #IBRX #ANKTIVA #TradingIntel #Biotech

$IBRX- $IBRX INTEL: MARKETING VS. MEDICINE ($6.54 SHAKEOUT) The market just underwent a -30% "liquidity raid" based on a headline that requires a deep forensic read. If you sold the $6.54 bottom, you traded on fear. If you bought the $7.50+ recovery, you traded on data. 1. THE "SLAP": AD COPY, NOT CLINICALS The FDA Warning Letter is a marketing compliance issue. The FDA’s OPDP office is penalizing PSS for aggressive podcast/TV ad claims. Crucial: This is NOT a product recall. The drug’s safety, efficacy, and current FDA approval for bladder cancer remain 100% intact. 2. THE $6.54 LIQUIDITY VACUUM We saw a complete failure of the $9.30 floor as stop-losses were hunted down to a flash-crash low of $6.54. The Read: The gap between $6.54 and the 7.50 recovery was fueled by institutional "Whales" recognizing a sentiment overreaction. They filled their bags while retail panicked over a marketing dispute. 3. THE SEPARATION OF CHURCH & STATE The FDA office reviewing the Papillary sBLA (Day 15 window) is separate from the office policing TV ads. A "Marketing Warning" does not legally stop a "Clinical Filing Acceptance." THE BOTTOM LINE: PSS pushed the envelope on marketing and got a public slap on the wrist. Status: V-Recovery in Progress. Support: $7.50. #IBRX #ANKTIVA #TradingIntel #Biotech

$IBRX- That warning letter is rough.. Did not see it coming..

$IBRX- $IBRX Short INTELLIGENCE REPORT: MARCH 23, 2026. As always data attached ( short interest data) Today was not just a green day; it was a structural shift in $IBRX market mechanics. The "Short Trap" has moved from theory to reality. 1. THE TAPE: BREAKOUT & ABSORPTION The Breach: $IBRX decisively cleared the $9.30 resistance, hitting an intraday high of $9.54. The Whale Signature: A massive 695,962-share block hit at the $9.40 close ($6.5M+). This signals institutional "buy-in," not retail flipping. Volume: 26.7M shares extreme conviction fueled by a "Wall of Analysts" (BTIG $13 target / D. Boral $23 target). 2. MECHANICAL FAILURE: SHORT EXHAUSTION Utilization: Pinned at 100%. There is zero remaining "legal" inventory to borrow. Inventory Crisis: IBKR availability dropped to a staggering 200 shares tonight. Shorts are out of ammo to defend the $10.00 magnet. Borrow Fees: Averaging 11.25% (Max 13.14%). Shorts are paying predatory interest to stay underwater. 3. THE CATALYST CLOCK FDA Window: Today is Day 14 since the sBLA resubmission. The market is betting on a Class 1 (60-day) designation, moving the finish line to May. THE BOTTOM LINE: We closed at $9.40 (+11%) on massive volume. $9.30 is now the floor. With zero borrow and a Gamma Trap set, the path of least resistance is UP. #IBRX #ANKTIVA #ShortSqueeze #Biotech

$IBRX- Marc 23rd UPDATE: THE $9.30 BATTLE IS HERE $IBRX Family, listen up. We are at a structural "Breaking Point" today. While the broader market is distracted, the tape is revealing a massive tug-of-war for the soul of this stock. The Situation: Shorts are Cornered This morning, $IBRX gapped up and touched $9.38, officially blowing past Friday’s "options pin." Since then, we have seen aggressive "Short-Exempt" selling hitting the bid to keep us under the $9.30 mark. Why are they so desperate? 100% Utilization: There are officially ZERO shares left to borrow (Ortex confirms only ~15k available). They are literally recycling the same "ghost shares" to suppress the price. The $9.32 Wall: This was Friday's manipulation high. Breaking and holding above this level triggers a massive wave of mechanical stop-losses for the shorts. The Catalyst: The "Wall of Analysts" BTIG: Initiated with a BUY ($13 Target) this morning. D. Boral (Jason Kolbert): Reaffirmed his $23.00 Target today. The Message: The "Smart Money" is pricing this for a $10B+ valuation while the shorts are fighting over pennies at $9.15. The Game Plan The shorts are "leaning" on the $9.17–$9.30 wall. They are hoping you get bored and sell. Don't. Watch $9.00: This has become a massive institutional support floor. Watch the Break: If we clear $9.40 on high volume this afternoon, the "Squeeze" moves from a theory to a reality. Bottom Line: We have the science, the revenue (Saudi/Macau), and the analyst upgrades. The shorts only have a 14,000-share wall at $9.17. That wall is made of paper. Patience is the only thing they can’t beat. #IBRX #ANKTIVA #ShortSqueeze